Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer

NCT00477282 is registered in ClinicalTrials.gov with BioNumerik Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00477282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00477282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer
Lead sponsor
BioNumerik Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2007
Completion date
June 30, 2013
Enrollment
509 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer